ClinicalTrials.gg

Program

SHR-3045

A development code. Also written as “SHR-3045 Injection”.

In Jiangsu HengRui Medicine's pipeline, PD-1. Its studies are mostly in Arthritis, Rheumatoid, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Nov 13, 20253 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine31 open or runningphase 2since Nov 13, 2025Mar 13, 2025none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-3045, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 13, 2025First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06883695 · 40 enrolled · China
  2. Sep 23, 2025Phase 1 study in Arthritis, RheumatoidNCT07200596 · 16 enrolled · China
  3. Nov 13, 2025Phase 2 study in Moderate to Severe Active Rheumatoid ArthritisNCT07233655 · 30 enrolled · China

TargetBeta

“PD-1”the company's pipeline, read by Claude · source

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07233655Moderate to Severe Active Rheumatoid Arthritis · China2Active, not recruitingApr 21, 202630
NCT07200596Arthritis, Rheumatoid · China1CompletedMar 31, 202616
NCT06883695Arthritis, Rheumatoid · China1CompletedJun 17, 202540

How it is read

Names in the registry

  • “SHR-3045 Injection”, 3 entries

Codes read as this program: SHR3045.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.